12.1 Anemia Management: ESAs & Intravenous Iron Therapy

Anemia Management: ESAs & Intravenous Iron Therapy

Chronic anemia is a common complication of end-stage renal disease (ESRD) that profoundly impairs physical function, cognitive performance, and cardiovascular stability. Left untreated, severe renal anemia accelerates left ventricular hypertrophy (LVH), congestive heart failure, and mortality in maintenance hemodialysis patients. Modern nephrology nursing requires an in-depth understanding of the hormonal regulation of erythropoiesis, the safe administration of erythropoiesis-stimulating agents (ESAs), the biological mechanics of oral hypoxia-inducible factor stabilizers, and the precise titration of intravenous (IV) iron.

---

Pathophysiology of Anemia in CKD and ESRD

The anemia of chronic kidney disease is predominantly normocytic and normochromic, arising from a multifactorial cascade of endocrine, hematologic, and inflammatory defects:

1. Endogenous Erythropoietin (EPO) Deficiency: Under physiological conditions, specialized peritubular interstitial fibroblasts in the renal cortex synthesize more than 90% of circulating erythropoietin in response to local tissue hypoxia. In progressive CKD, interstitial changes impair the appropriate EPO response to anemia; iron availability, inflammation and blood loss can also contribute. Erythrocyte colony-forming units (CFU-E) in the bone marrow undergo premature apoptosis without survival signals from EPO.
2. Shortened Red Blood Cell Lifespan: Normal erythrocytes circulate for approximately 120 days. In the uremic milieu, red cell survival is reduced to 60 to 90 days (approximately a 25% to 50% reduction in this illustrative range). Uremic guanidines, oxidative stress, and lipid peroxidation stiffen the erythrocyte membrane, inhibit the membrane $Na^+/K^+$-ATPase pump, and increase osmotic fragility, driving premature splenic and reticuloendothelial phagocytosis.
3. Extracorporeal Circuit Blood Trapping & Phlebotomy: Hemodialysis patients experience unavoidable, recurrent blood losses. Dialyzer membrane residual trapping, blood tubing retention, circuit clotting, and routine laboratory draws account for 1 to 3 liters of whole blood loss annually. Repeated losses can deplete iron, but the amount varies with hemoglobin, circuit loss and sampling. A fixed blood-volume loss does not imply one universal annual iron deficit.
4. Hepcidin Elevation & Reticuloendothelial Iron Blockade: Maintenance hemodialysis is characterized by chronic, low-grade systemic inflammation (elevated interleukin-6 and TNF-alpha). Proinflammatory cytokines stimulate hepatic transcription of hepcidin, the master iron regulatory hormone. Circulating hepcidin binds to, internalizes, and degrades ferroportin, the sole cellular iron export channel on duodenal enterocytes and reticuloendothelial macrophages. Consequently, absorbed dietary iron remains trapped in intestinal enterocytes, and recycled iron remains locked within splenic and hepatic macrophages, creating functional iron deficiency where bone marrow cannot access stored iron.

---

Erythropoiesis-Stimulating Agents (ESAs)

Recombinant DNA technology provides exogenous erythropoietin analogs to stimulate erythroid proliferation and differentiation:

• Epoetin Alfa (Epogen, Procrit): A recombinant human erythropoietin identical in amino acid sequence to native EPO, possessing three N-linked carbohydrate chains (molecular weight $\sim 30.4\text{ kDa}$). It has a short intravenous elimination half-life of 4 to 8 hours in hemodialysis. US labeling gives an adult starting regimen of 50–100 units/kg three times weekly, IV or subcutaneously, with IV recommended in HD. Maintenance and timing follow the actual product and ordered protocol.
• Darbepoetin Alfa (Aranesp): A hyperglycosylated ESA engineered with two additional N-linked carbohydrate chains (five total, molecular weight $\sim 37.1\text{ kDa}$). These added carbohydrate chains reduce receptor affinity but dramatically extend the circulating IV half-life to approximately 25 hours (three-fold longer than epoetin alfa). It is administered weekly or every two weeks.
• Methoxy Polyethylene Glycol-Epoetin Beta (Mircera / CERA): A Continuous Erythropoietin Receptor Activator synthesized by conjugating epoetin beta with a linear 30 kDa methoxy polyethylene glycol polymer (molecular weight $\sim 60\text{ kDa}$). This massive hydrodynamic volume slows receptor association and dissociation, producing an extended elimination half-life of approximately 130 hours IV. It is administered once every two to four weeks.

Clinical Administration & Pure Red Cell Aplasia (PRCA)

In hemodialysis, ESAs are routinely administered intravenously into the venous drip chamber or venous port during rinseback to eliminate painful subcutaneous injections. Rarely, patients develop neutralizing anti-erythropoietin antibodies that cross-react with endogenous EPO and all recombinant ESAs, causing Pure Red Cell Aplasia (PRCA). PRCA manifests as a sudden drop in hemoglobin of $>1.0\text{ g/dL/week}$ or severe transfusion dependence, with absolute reticulocytopenia ($<10,000/\mu\text{L}$) and absent bone marrow erythroblasts. When PRCA is diagnosed, all ESAs must be discontinued immediately and permanently; switching to another ESA is contraindicated, and subsequent treatment is specialist-directed.

---

Hemoglobin Goals and Safety

KDIGO 2026 generally favors ESA initiation around hemoglobin 9–10 g/dL in dialysis and recommends an adult ESA maintenance target below 11.5 g/dL, individualized to symptoms and transfusion risk. This does not create a universal 10–11.5 target for every patient. US epoetin labeling directs use of the lowest dose sufficient to reduce transfusions and reduction or interruption if hemoglobin approaches or exceeds 11 g/dL in dialysis. A US nurse follows the actual ordered protocol and applicable product labeling rather than treating KDIGO’s upper limit as permission to continue unchanged at 11.4.

ESAs carry boxed warnings for death, cardiovascular events, thrombosis and other risks. Monitor blood pressure, hemoglobin trend, dose response and access thrombosis risk. Correct iron deficiency and assess inflammation, bleeding or other causes before escalating for hyporesponsiveness. An abrupt hemoglobin fall requires evaluation rather than automatic dose doubling. Uncontrolled hypertension is a contraindication to epoetin treatment. Sudden severe anemia with reticulocytopenia may require evaluation for pure red-cell aplasia; the specialist determines testing and subsequent treatment.

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs)

HIF-PHIs (such as daprodustat and vadadustat) represent an oral class of agents for dialysis-dependent CKD anemia. In normoxic states, prolyl hydroxylase domain (PHD) enzymes hydroxylate proline residues on hypoxia-inducible factor alpha ($HIF-1\alpha$ and $HIF-2\alpha$). Hydroxylated HIF-alpha is recognized by the von Hippel-Lindau (VHL) protein, which directs it to the proteasome for degradation.

HIF-PHIs reversibly inhibit PHD enzymes, preventing HIF-alpha degradation. Stabilized HIF-alpha translocates into the nucleus, dimerizes with HIF-beta, and activates hypoxia response elements on target genes. This triggers a coordinated physiologic response:

1. Stimulates endogenous EPO transcription in cortical peritubular fibroblasts and hepatocytes.
2. Suppresses hepatic hepcidin synthesis, unlocking reticuloendothelial iron stores.
3. Upregulates duodenal iron transport proteins (DCYTB, DMT1, and ferroportin), significantly enhancing intestinal iron absorption.

---

Intravenous Iron Therapy & Monitoring

Effective erythropoiesis requires adequate bioavailable iron. Blood loss and inflammation-related iron restriction often make oral replacement insufficient in HD. KDIGO 2026 favors IV over oral iron when initiating therapy in HD, with review of infection and the overall clinical situation. Intravenous (IV) iron therapy is the clinical standard of care.

Iron Biomarkers and KDIGO 2026

TSAT estimates circulating iron availability, whereas ferritin reflects stores and can rise with inflammation. KDIGO 2026 suggests initiating iron in anemia with HD when ferritin is at most 500 ng/mL and TSAT at most 30%. Withhold routine iron when ferritin is above 700 ng/mL or TSAT at least 40%; consider suspending iron during active systemic infection. Interpret trends, blood loss, response and the ordered protocol rather than diagnosing overload from ferritin alone.

IV Iron Formulations Comparison

All IV iron products require readiness to recognize and treat hypersensitivity. Observe for at least the labeled period and until stable after administration; no test-dose exemption eliminates serious reaction risk.

Sources checked 2026-10-10: KDIGO 2026 anemia, epoetin label, ferumoxytol label

Product sources checked 2026-10-11: Venofer label, Ferrlecit label.